Summary: Cannabinol (CBN), a cannabinoid derived from cannabis, offers neuroprotective properties that could treat neurological disorders like Alzheimer’s, Parkinson’s, and traumatic brain injuries. Their study details how CBN and its newly developed analogs prevent mitochondrial dysfunction in neurons, a common factor in these diseases. The team synthesized four CBN-based compounds, finding one, in particular, to […]
Fibroblast growth factor receptor inhibitors, commonly used in cancer treatment, could effectively reduce neurological symptoms in patients with post-treatment Lyme disease syndrome. The study shows these inhibitors can decrease inflammation and cell death in brain and nerve tissues affected by Lyme disease.
Engaging in complex, thought-provoking work may lower the risk of mild cognitive impairment (MCI) in older age. Conducted by researchers at Oslo University Hospital, the study analyzed job demands of over 7,000 people across 305 occupations in Norway, linking higher cognitive job demands in one’s 30s through 60s to a reduced incidence of MCI post-70.
Researchers employed AI to fast-track the discovery of treatments for Parkinson’s disease. They utilized machine learning techniques to screen millions of compounds and successfully identified five promising candidates that prevent the harmful clumping of alpha-synuclein, a key protein in Parkinson’s pathology.
Common HIV drugs could reduce the incidence of Alzheimer’s disease (AD). Utilizing anonymized prescription data from over 225,000 individuals, the study found that HIV-positive patients taking reverse transcriptase (RT) inhibitors showed a significantly lower rate of AD compared to the general population.